.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,932,247

« Back to Dashboard
Patent 5,932,247 protects ALLEGRA, ALLEGRA ALLERGY, ALLEGRA HIVES, CHILDREN'S ALLEGRA ALLERGY, and CHILDREN'S ALLEGRA HIVES, and is included in two NDAs. There has been one Paragraph IV challenge on Allegra. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for ALLEGRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-three patent family members in twenty-three countries.

Summary for Patent: 5,932,247

Title: Pharmaceutical composition for piperidinoalkanol compounds
Abstract:The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Inventor(s): Ortyl; Thomas T. (Overland Park, KS), Skultety; Paul F. (Leawood, KS), Mitchell; Kristen C. (Lee's Summit, MO), Phadke; Deepak S. (Olathe, KS), Attarchi; Faraneh (Kansas City, MO), Pierce; Marguerite L. (Fairway, KS), Schoeneman; Aaron W. (Lee's Summit, MO), Schnitz; Joseph M. (Kansas City, MO)
Assignee: Hoechst Marion Roussel, Inc. (Cincinnati, OH)
Application Number:08/948,005
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 41st percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
ALLEGRA
fexofenadine hydrochloride
CAPSULE;ORAL020625-001Jul 25, 1996DISCNNo5,932,247*PED► subscribe
Sanofi Aventis Us
ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-007Jan 24, 2011OTCNo5,932,247*PED► subscribe
Sanofi Aventis Us
ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-010Jan 24, 2011OTCYes5,932,247*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,932,247

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,129,408Pharmaceutical composition for piperidinoalkanol compounds► subscribe
5,738,872 Pharmaceutical composition for piperidinoalkanol compounds► subscribe
5,855,912 Pharmaceutical compositions for piperidinalkanol compounds► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,932,247

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina003929► subscribe
Austria226819► subscribe
Australia4909896► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc